Forecast Of The Day: Boston Scientific’s Cardiac Rhythm Management Revenue
What?
Boston Scientific (NYSE:BSX) Revenue from Cardiac Rhythm Management rose from around $1.94 billion in 2019 to $2 billion in 2021. Trefis expects the metric to grow to about $2.15 billion by 2024.
Why?
Relevant Articles
- Should You Pick Boston Scientific Stock After A Solid Q4 And 13% Uptick This Year?
- What’s Next For Boston Scientific Stock After 5% Gains In A Week?
- Should You Pick MGM Resorts Over Boston Scientific Stock For Better Returns?
- Which Is A Better Buy – Boston Scientific Stock Or Abbott?
- What’s Next For Boston Scientific Stock After Outperforming During The 2022 Inflation Shock?
- New Product Launches To Aid Boston Scientific’s Q1
We expect growth to be driven by new products, as well as higher instances of cardiac disease.
So What?
We remain positive on BSX stock with a $49 price estimate, which is about 5% ahead of the current market price.
What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.
| Returns | Dec 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
| BSX Return | 2% | 9% | 114% |
| S&P 500 Return | -6% | -20% | 71% |
| Trefis Multi-Strategy Portfolio | -7% | -23% | 210% |
[1] Month-to-date and year-to-date as of 12/28/2022
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates
See all Trefis Price Estimates